Normalisation of physical function by infliximab in patients with RA: Factors associated with normal physical function

Hayato Nagasawa, Hideto Kameda, Naoya Sekiguchi, Koichi Amano, Tsutomu Takeuchi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: We conducted a two-year prospective study to identify possible factors associated with normalisation of physical function by infliximab treatment in 125 patients with rheumatoid arthritis (RA). Methods RA patients who had been scheduled to receive infliximab at 3 mg/kg were registered and prospectively examined for disease activity, joint damage, and physical function for 102 weeks using the Disease Activity Score of 28 Joints (DAS-28) using C-reactive protein, van der Heijde-modified Sharp score (vdH-Sharp score) of hand and foot x-ray, and Health Assessment Questionnaire Disability Index (HAQ-DI). Normal physical function and clinical remission were defined as a HAQ-DI of 0.5 or less, and DAS28 (CRP) <2.6, respectively. Results: Forty-two of 125 patients (42%) achieved normal physical function at 102 weeks. The percentage of normal physical function at 102 weeks was significantly higher in the patients achieving clinical remission at 102 weeks (60%) than in those without (16%). In the patients with clinical remission at 102 weeks, less structural damage at baseline was correlated with a higher rate of normal physical function, suggesting the critical importance of joint destruction prior to infliximab therapy, in addition to clinical response. Logistic regression analysis further identified HAQ-DI, serum MMP-3 level, vdH-Sharp score, and methotrexate (MTX) dose as baseline factors contributing to normal physical function with 2-year infliximab treatment. Conclusion: Treatment with anti-TNF biologics in combination with MTX may achieve the normalisation of physical function in patients with established RA. Critical factors contributing to the normalisation of function were tight control of disease activity and less joint damage.

Original languageEnglish
Pages (from-to)365-372
Number of pages8
JournalClinical and Experimental Rheumatology
Volume28
Issue number3
Publication statusPublished - 2010

Fingerprint

Rheumatoid Factor
Rheumatoid Arthritis
Joints
Methotrexate
Health
Joint Diseases
Therapeutics
Biological Products
Matrix Metalloproteinases
C-Reactive Protein
Infliximab
Foot
Hand
Logistic Models
Regression Analysis
X-Rays
Prospective Studies
Serum
Surveys and Questionnaires

Keywords

  • Disease Activity Score of 28 joints (DAS28)
  • Health Assessment Questionnaire Disability Index (HAQ-DI)
  • Infliximab
  • Rheumatoid arthritis
  • Van der Heijde-modification of the Sharp score (vdH-Sharp score)

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Normalisation of physical function by infliximab in patients with RA : Factors associated with normal physical function. / Nagasawa, Hayato; Kameda, Hideto; Sekiguchi, Naoya; Amano, Koichi; Takeuchi, Tsutomu.

In: Clinical and Experimental Rheumatology, Vol. 28, No. 3, 2010, p. 365-372.

Research output: Contribution to journalArticle

@article{881ab27049ac4180a2cd0fdb8d3cddcc,
title = "Normalisation of physical function by infliximab in patients with RA: Factors associated with normal physical function",
abstract = "Objectives: We conducted a two-year prospective study to identify possible factors associated with normalisation of physical function by infliximab treatment in 125 patients with rheumatoid arthritis (RA). Methods RA patients who had been scheduled to receive infliximab at 3 mg/kg were registered and prospectively examined for disease activity, joint damage, and physical function for 102 weeks using the Disease Activity Score of 28 Joints (DAS-28) using C-reactive protein, van der Heijde-modified Sharp score (vdH-Sharp score) of hand and foot x-ray, and Health Assessment Questionnaire Disability Index (HAQ-DI). Normal physical function and clinical remission were defined as a HAQ-DI of 0.5 or less, and DAS28 (CRP) <2.6, respectively. Results: Forty-two of 125 patients (42{\%}) achieved normal physical function at 102 weeks. The percentage of normal physical function at 102 weeks was significantly higher in the patients achieving clinical remission at 102 weeks (60{\%}) than in those without (16{\%}). In the patients with clinical remission at 102 weeks, less structural damage at baseline was correlated with a higher rate of normal physical function, suggesting the critical importance of joint destruction prior to infliximab therapy, in addition to clinical response. Logistic regression analysis further identified HAQ-DI, serum MMP-3 level, vdH-Sharp score, and methotrexate (MTX) dose as baseline factors contributing to normal physical function with 2-year infliximab treatment. Conclusion: Treatment with anti-TNF biologics in combination with MTX may achieve the normalisation of physical function in patients with established RA. Critical factors contributing to the normalisation of function were tight control of disease activity and less joint damage.",
keywords = "Disease Activity Score of 28 joints (DAS28), Health Assessment Questionnaire Disability Index (HAQ-DI), Infliximab, Rheumatoid arthritis, Van der Heijde-modification of the Sharp score (vdH-Sharp score)",
author = "Hayato Nagasawa and Hideto Kameda and Naoya Sekiguchi and Koichi Amano and Tsutomu Takeuchi",
year = "2010",
language = "English",
volume = "28",
pages = "365--372",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "3",

}

TY - JOUR

T1 - Normalisation of physical function by infliximab in patients with RA

T2 - Factors associated with normal physical function

AU - Nagasawa, Hayato

AU - Kameda, Hideto

AU - Sekiguchi, Naoya

AU - Amano, Koichi

AU - Takeuchi, Tsutomu

PY - 2010

Y1 - 2010

N2 - Objectives: We conducted a two-year prospective study to identify possible factors associated with normalisation of physical function by infliximab treatment in 125 patients with rheumatoid arthritis (RA). Methods RA patients who had been scheduled to receive infliximab at 3 mg/kg were registered and prospectively examined for disease activity, joint damage, and physical function for 102 weeks using the Disease Activity Score of 28 Joints (DAS-28) using C-reactive protein, van der Heijde-modified Sharp score (vdH-Sharp score) of hand and foot x-ray, and Health Assessment Questionnaire Disability Index (HAQ-DI). Normal physical function and clinical remission were defined as a HAQ-DI of 0.5 or less, and DAS28 (CRP) <2.6, respectively. Results: Forty-two of 125 patients (42%) achieved normal physical function at 102 weeks. The percentage of normal physical function at 102 weeks was significantly higher in the patients achieving clinical remission at 102 weeks (60%) than in those without (16%). In the patients with clinical remission at 102 weeks, less structural damage at baseline was correlated with a higher rate of normal physical function, suggesting the critical importance of joint destruction prior to infliximab therapy, in addition to clinical response. Logistic regression analysis further identified HAQ-DI, serum MMP-3 level, vdH-Sharp score, and methotrexate (MTX) dose as baseline factors contributing to normal physical function with 2-year infliximab treatment. Conclusion: Treatment with anti-TNF biologics in combination with MTX may achieve the normalisation of physical function in patients with established RA. Critical factors contributing to the normalisation of function were tight control of disease activity and less joint damage.

AB - Objectives: We conducted a two-year prospective study to identify possible factors associated with normalisation of physical function by infliximab treatment in 125 patients with rheumatoid arthritis (RA). Methods RA patients who had been scheduled to receive infliximab at 3 mg/kg were registered and prospectively examined for disease activity, joint damage, and physical function for 102 weeks using the Disease Activity Score of 28 Joints (DAS-28) using C-reactive protein, van der Heijde-modified Sharp score (vdH-Sharp score) of hand and foot x-ray, and Health Assessment Questionnaire Disability Index (HAQ-DI). Normal physical function and clinical remission were defined as a HAQ-DI of 0.5 or less, and DAS28 (CRP) <2.6, respectively. Results: Forty-two of 125 patients (42%) achieved normal physical function at 102 weeks. The percentage of normal physical function at 102 weeks was significantly higher in the patients achieving clinical remission at 102 weeks (60%) than in those without (16%). In the patients with clinical remission at 102 weeks, less structural damage at baseline was correlated with a higher rate of normal physical function, suggesting the critical importance of joint destruction prior to infliximab therapy, in addition to clinical response. Logistic regression analysis further identified HAQ-DI, serum MMP-3 level, vdH-Sharp score, and methotrexate (MTX) dose as baseline factors contributing to normal physical function with 2-year infliximab treatment. Conclusion: Treatment with anti-TNF biologics in combination with MTX may achieve the normalisation of physical function in patients with established RA. Critical factors contributing to the normalisation of function were tight control of disease activity and less joint damage.

KW - Disease Activity Score of 28 joints (DAS28)

KW - Health Assessment Questionnaire Disability Index (HAQ-DI)

KW - Infliximab

KW - Rheumatoid arthritis

KW - Van der Heijde-modification of the Sharp score (vdH-Sharp score)

UR - http://www.scopus.com/inward/record.url?scp=77957014531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957014531&partnerID=8YFLogxK

M3 - Article

C2 - 20525444

AN - SCOPUS:77957014531

VL - 28

SP - 365

EP - 372

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 3

ER -